All In Biotech

Drug Trial Radar · NCT04673617

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 With Immunotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin.

Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

45

Actual

Start

Mar 29, 2021

Primary completion

Oct 6, 2025

Study completion Oct 6, 2025

Sponsor

Lead sponsor
Artiva Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells. This clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as follows: 1) to evaluate the safety of AB-101 given alone or in combination with rituximab (including the DLBCL specific cohort) or in combination with bendamustine and rituximab; 2) to evaluate the potential clinical activity of AB-101 when given in combination with rituximab or in combination with bendamustine and rituximab (combination cohorts only); and 3) to identify the recommended Phase 2 dose (RP2D). The primary objective of Phase 2 is to determine whether AB-101 in combination with rituximab or in combination with bendamustine and rituximab has anti-cancer activity in patients. Patients will be assigned to receive either AB-101 alone as monotherapy, in combination with rituximab (including DLBCL specific cohort) or in combination with bendamustine and rituximab. All patients will receive at least 1 treatment cycle of AB-101, followed by scheduled assessments of overall health and tumor response. Patients receiving AB-101 in combination with rituximab may receive up to 3 additional cycles of treatment. Patients receiving AB-101 in combination with bendamustine and rituximab may receive up to 5 additional cycles of treatment. Patients enrolled into the DLBCL specific cohort receiving AB-101 in combination with rituximab may receive up to 3 cycles of treatment.

Conditions

  • Non Hodgkin Lymphoma

Interventions

  • AB-101Drug

    NK cell therapy

  • RituximabDrug

    Anti-CD20 antibody therapy

  • Interleukin-2Drug

    Immune cytokine

  • CyclophosphamideDrug

    Lymphodepleting chemotherapy

  • FludarabineDrug

    Lymphodepleting chemotherapy

  • BendamustineDrug

    Chemoimmunotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Safety and tolerability of AB-101 as monotherapy, and in combination with rituximab (including the DLBCL specific cohort) and in combination with bendamustine and rituximab.Time frame: From the ICF signature through 13 weeks after last study drug dose.
  2. Phase 1, combination therapy: AB-101 clinical activity, determined by ORRTime frame: From baseline disease assessment through end of study participation.
  3. Phase 1, combination therapy: Identify the recommended Phase 2 dose (R2PD) for AB-101.Time frame: From ICF signature through 13 weeks after last study drug dose.
  4. Phase 2: Determine the efficacy profile of AB-101 in combination with rituximab or in combination with bendamustine and rituximab when administered to patients with R/R NHL of B-cell origin.Time frame: From baseline disease assessment through end of study participation.

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Artiva Clinical Trial Site

    Birmingham, Alabama

  • Artiva Clinical Trial Site

    Tucson, Arizona

  • Artiva Clinical Trial Site

    Orange, California

  • Artiva Clinical Trial Site

    San Diego, California

  • Artiva Clinical Trial Site

    Gainesville, Florida

  • Artiva Clinical Trial Site

    Atlanta, Georgia

  • Artiva Clinical Trial Site

    Chicago, Illinois

  • Artiva Clinical Trial Site

    Iowa City, Iowa

  • Artiva Clinical Trial Site

    Wichita, Kansas

  • Artiva Clinical Trial Site

    Louisville, Kentucky

  • Artiva Clinical Trial Site

    Detroit, Michigan

  • Artiva Clinical Trial Site

    Lake Success, New York

  • Artiva Clinical Trial Site

    New York, New York

  • Artiva Clinical Trial Site

    Columbus, Ohio

  • Artiva Clinical Trial Site

    Portland, Oregon

  • Artiva Clinical Trial Site

    Philadelphia, Pennsylvania

  • Artiva Clinical Trial Site

    Philadelphia, Pennsylvania

  • Artiva Clinical Trial Site

    Providence, Rhode Island

  • Artiva Clinical Trial Site

    Dallas, Texas

  • Artiva Clinical Trial Site

    Salt Lake City, Utah

  • Artiva Clinical Trial Site

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.